Markman Opinion

Shares of Celgene (NASDAQ: CELG) are volatile following the report of the Markman opinion on a patent dispute over five claims covering six patents with defendants Natco Pharma Limited, Arrow International Limited, and Watson Laboratories seeking approval to market a generic version of Revlimid...